Cargando…

Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence

PURPOSE: Real-time detection and intervention can be used as potential measures to markedly decrease breast cancer mortality. Assessment of circulating tumor DNA (ctDNA) may offer great benefits for the management of breast cancer over time. However, the use of ctDNA to predict the effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hao, Shuai, Tian, Wuguo, Zhao, Jianjie, Chen, Yi, Zhang, Xiaohua, Gao, Bo, He, Yujun, Luo, Donglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462818/ https://www.ncbi.nlm.nih.gov/pubmed/32908788 http://dx.doi.org/10.4048/jbc.2020.23.e41

Ejemplares similares

Application of Nano-Carbon in Lymph Node Dissection for Thyroid Cancer and Protection of Parathyroid Glands
por: Tian, Wuguo, et al.
Publicado: (2014)

Whole Exome Sequencing in the Male Breast Cancer with Prolactinoma: A Case Report and Literature Review
por: Hao, Shuai, et al.
Publicado: (2020)

Analysis and prediction model of ferroptosis related genes in breast cancer
por: Wang, Lingli, et al.
Publicado: (2022)

Lobaplatin inhibits breast cancer progression, cell proliferation while it induces cell apoptosis by downregulating MTDH expression
por: Tian, Wuguo, et al.
Publicado: (2018)

Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials
por: Hao, Shuai, et al.
Publicado: (2017)

Peri-Operative Treatment of Giant Nodular Goiter
por: Gao, Bo, et al.
Publicado: (2012)

Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells
por: Li, Zhirong, et al.
Publicado: (2017)

MicroRNA‐374c‐5p inhibits the development of breast cancer through TATA‐box binding protein associated factor 7‐mediated transcriptional regulation of DEP domain containing 1
por: Hao, Shuai, et al.
Publicado: (2019)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy
por: Lin, Po-Han, et al.
Publicado: (2021)

Comparison of Diagnostic Accuracy of Real-Time Elastography and Shear Wave Elastography in Differentiation Malignant From Benign Thyroid Nodules
por: Tian, Wuguo, et al.
Publicado: (2015)

MicroRNA-766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway
por: Zhao, Jianjie, et al.
Publicado: (2022)

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
por: Chen, Yu-Hsiang, et al.
Publicado: (2017)

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
por: Cavallone, Luca, et al.
Publicado: (2020)

Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Li, Shunying, et al.
Publicado: (2020)

Primary malignant melanoma of the breast: A case report and review of the literature
por: HE, YUJUN, et al.
Publicado: (2014)

Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer
por: Kaigorodova, Evgeniya V., et al.
Publicado: (2018)

Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
por: Förnvik, Daniel, et al.
Publicado: (2019)

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients
por: Yue, Dongsheng, et al.
Publicado: (2022)

Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer
por: Butler, Timothy M., et al.
Publicado: (2019)

Circulating T-Cell Repertoires Correlate With the Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Cai, Gengxi, et al.
Publicado: (2022)

Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma
por: Wang, Jian, et al.
Publicado: (2020)

Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer
por: Zhang, Jinghua, et al.
Publicado: (2021)

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
por: Parsons, Heather A., et al.
Publicado: (2023)

Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy
por: Jakabova, Anna, et al.
Publicado: (2021)

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity
por: Yang, Xiao, et al.
Publicado: (2022)

Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring
por: ALEMZADEH, EFFAT, et al.
Publicado: (2023)

Circulating tumor DNA analysis detects micrometastatic disease and predicts recurrence in a patient with colon cancer: A case report
por: Luo, Jiamin, et al.
Publicado: (2023)

Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients
por: Gwark, Sungchan, et al.
Publicado: (2020)

Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates
por: Chedid, Julien, et al.
Publicado: (2022)

Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers
por: Addanki, Sridevi, et al.
Publicado: (2022)

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
por: Huffman, Brandon M., et al.
Publicado: (2022)

Exploring circulating micro‐RNA in the neoadjuvant treatment of breast cancer
por: Casey, Máire‐Caitlín, et al.
Publicado: (2016)

Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Cirmena, Gabriella, et al.
Publicado: (2020)

Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
por: Chitalia, Rhea, et al.
Publicado: (2023)

Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
por: Zhu, Gui‐Qi, et al.
Publicado: (2021)

Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer
por: Ni, Chao, et al.
Publicado: (2020)

Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy
por: Kim, Gina, et al.
Publicado: (2023)

Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
por: Todorova, Valentina K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_930gt29crijav8t7ra9sme008j